REMARKS

In accordance with 37 C.F.R. § 1.121, a marked up copy of the presently amended paragraph of the specification is appended hereto. Deletions to the originally filed text are noted by bracketing. Additions are noted by underlining.

The Commissioner is hereby authorized to charge any fees for this submission that may be incurred or credit any overpayment of fees to Deposit Account No. 50-1273. The Examiner is invited to contact Applicants' undersigned Representative if it is believed that prosecution may be furthered hereby.

Respectfully Submitted,

BROBECK, PHLEGER & HARRISON LLP

By: _____
Jeffrey W. Guise
Reg. No.: 34,613

Brobeck, Phleger & Harrison LLP
12390 El Camino Real
San Diego, CA 92130
(858) 720-2500

anti-Human κ or λ-HRP (Fischer, Pittsburgh, PA)1:2000 in TBSB, 100µl was added to wells, and incubated for 1 hour at 22 °C. The wells were washed 6 times with 200µl TBST. One hundred µl of substrate (TMB 1 component, KPL Inc., Gaithersburg, MD) was added to wells, developed 30 min. and assayed at $OD_{620}$.

**d. Idiotypic Protein Release Criteria:** (1) The DNA sequence of idiotype-variable genes in baculovirus from production supernantant must be identical to the DNA sequence in the production vector. (2) The idiotypic protein concentration was greater than 0.5 mg/ml based on $OD_{280}$. (3) The major peak area was greater than 90% of area in evaluated peaks on Superose 6 analytical chromatography. (4) The major chromatographic peak corresponds to the human IgGκ (or λ) ELISA activity peak.

The final vaccine product, Id-KLH, was tested for endotoxin levels by a kinetic turbidity microplate assay or a Limulus Amoebocyte Lysate (LAL) assay and had a level below 350 endotoxin units (EU) per ml. Ten percent of the lot was tested for sterility on a 14-day test and tests negative or was discarded.

Table 3 shows a summary of primer sequences used for establishing final product identity.

**TABLE 3. Primer Sequences Used for Establishing Final Product Identity.**

| PRIMER NAME | PRIMER SEQUENCE (5' 3') |
|---|---|
| | |
| 1. Human Placental Alkaline Phosphatase Internal | AAATGATAACCATCTCGC (SEQ ID NO:25) |
| 2. Human Placental Alkaline Phosphatase External | TTTACTGTTTTCGTAACAGTTTTG (SEQ ID NO:26) |
| 3. Kappa Light Chain Constant Antisense | TTGGAGGGCGTTATCCACCTTC (SEQ ID NO:27) |
| 4. Kappa Light Chain Constant Downstream Internal | CTGTAAATCAACAACGCACAG (SEQ ID NO:28) |

| | |
|---|---|
| 5. Kappa Light Chain Constant Downstream External | CAACAACGCACAGAATCTAG (SEQ ID NO:29) |
| 6. Melittin Internal | GGGACCTTTAATTCAACCCAACAC (SEQ ID NO:30) |
| 7. Melittin External | AAACGCGTTGGAGTCTTGTGTGC (SEQ ID NO:31) |
| 8. $IgG_{\gamma 1}$ Heavy Chain Constant Downstream Internal | GGAAGTAGTCCTTGACCAGGCAG (SEQ ID NO:32) |
| 9. $IgG_{\gamma 1}$ Heavy Chain Constant Downstream Middle | CTGAGTTCCACGACACCGTCAC (SEQ ID NO:33) |
| 10. $IgG_{\gamma 1}$ Heavy Chain Constant Downstream External | TAGAGTCCTGAGGACTGTAGGAC (SEQ ID NO:34) |
| 11. Kappa & Lambda Downstream: | 5'-GGTCGTTAACAATGGGGAAGCTG-3' (SEQ ID NO:35) |
| 12. PH forward | 5'-TTTACTGTTTTCGTAACAGTTTTG-3' (SEQ ID NO:36) |
| 13. PH reverse | 5'-GGTCGTTAACAATGGGGAAGCTG-3' (SEQ ID NO:37) |
| 14. Lambda Constant Internal | 5'-GAAGTCACTTATGAGACACACCAG-3' (SEQ ID NO:38) |

## 8. USE OF CHIMERIC PROTEIN OF THE INVENTION FOR TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA:

$V_H$ and $V_L$ regions were obtained from a patient with Non-Hodgkin's B-Cell Lymphoma. Using the 5' RACE method described *supra*, genes encoding these regions were cloned and inserted into the expression vector and expressed by the methods of the instant invention. Table 5 contains the DNA sequences of the Vh and Vl regions used for the expression vector. The Apa I and Dra III sites used for cloning are indicated by underlining.